HGS targets patent-expiring drugs.
Hollon
T
T
D001709:Biotechnology / Q000331:legislation & jurisprudence*; D004345:Drug Industry; D006207:Half-Life; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D007370:Interferon Type I / Q000737:chemistry* / Q000493:pharmacokinetics*; D017387:Investigational New Drug Application; D010330:Patents as Topic; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000493:pharmacokinetics; D011994:Recombinant Proteins; D012709:Serum Albumin / Q000737:chemistry*
D007370:Interferon Type I; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D012709:Serum Albumin